Januvia (Sitagliptin Phosphate) a drug specifically made for Type 2 Diabetes and created by Merck & Co., is linked to health complications like hypoglycemia, kidney problems and pancreas inflammation. Furthermore, thyroid cancer is among the fatal adverse effects of the drug.
It was in October 2006 when Januvia was first approved as a class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing insulin production in the pancreas and decreasing sugar in the liver. Januvia is only taken once daily, and it is not to be used for patients that have Type 1 diabetes.
Statistics show that diabetes affects about 30 million Americans. So, it is no surprise that Januvia quickly became a bestselling drug and rained in profits to its manufacturer. While the market may seem kind to Januvia’s manufacturer, Plaintiffs began appearing and filing complaints against Merck & Co. citing that Januvia brought serious adverse effects.
Notable lawsuits against Januvia:
- Leeta Anderson. Leeta Andreson filed lawsuits against both Eli Lily and Company and Merck & Co., and alleged that the drug was the cause of her husband’s pancreatic cancer, which led to his death. The lawsuit was filed in California Federal Court in October 2013.
- In the same month, a man from Alabama filed lawsuits against the manufacturer for his wife’s death alleging that the drug was the reason for her pancreatic cancer.
- In March 2013, a lawsuit filed in Illinois state court claimed that three patients developed pancreatic cancer after being treated with Januvia.
A person who has been injured by Januvia‘s adverse effects may have grounds to file a suit against the manufacturer. You may be eligible for compensation for pain and suffering, lost wages, and medical bills.